View in EDS HTML Full Text PDF Full Text

Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US.

Saved in:

Bibliographic Details
Title:	Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US.
Authors:	Kuznik, Andreas¹ (AUTHOR) andreas.kuznik@regeneron.com, Coughlan, Anna² (AUTHOR), Pinsent, Amy³ (AUTHOR), Toro-Diaz, Hector² (AUTHOR), Sherman, Steven¹ (AUTHOR), Patel, Nimesh^4,5,6,7 (AUTHOR)
Source:	Ophthalmology & Therapy. Nov2025, Vol. 14 Issue 11, p2863-2875. 13p.
Database:	Academic Search Ultimate
Full text is not displayed to guests. Login for full access.

Description
ISSN:	21938245
DOI:	10.1007/s40123-025-01236-6